Company Profile

AxoGen Inc (AKA: Axogen Corporation~LecTec Corporation)
Profile last edited on: 9/5/2023      CAGE: 4BMD7      UEI: LUWQJP6W4BA9

Business Identifier: Treatment options for the reconstruction and repair of peripheral nerve injuries
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

13631 Progress Boulevard Suite 400
Alachua, FL 32615
   (386) 462-6800
Location: Single
Congr. District: 03
County: Alachua

Public Profile

AxoGen is a regenerative medicine company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and reconstruction to help patients suffering from traumatic injuries or undergoing surgeries that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Damage to a peripheral nerve can result in the loss of muscle or organ function, the loss of sensory feeling or pain and can significantly impact the patient's quality of life. The company has licensed technologies from University of Florida’s McKnight Brain Institute, the University of Texas and other research institutions, as well as developed its own technologies. The firm combines scientific advancements that reveal the mechanism of axon growth and regeneration, and have incorporated them into the company's products to help surgeons repair peripheral nerve damage. The AXOGEN nerve graft enables the repair and regeneration of peripheral nerves. It is an allograft nerve that is minimally processed to preserve the three dimensional structure and growth promoters while clearing the nerve graft from cellular materials and growth inhibitors. The resulting nerve graft provides a pathway for nerve regeneration without requiring immunosuppression. Formerly known as AxoGen Corporation, Axogen reverese merged with LecTec Corporation in 2011 and was subsequently renamed AxoGen, Inc.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2007 1 NIH $102,737
Project Title: Long distance nerve regeneration via processed allografts in a caprine model

Key People / Management

  Jamie Grooms -- President

  John P Engels

  Richard D Johnson

Company News

There are no news available.